NL0015001WM6 - Common Stock

We assign a fundamental rating of **6** out of 10 to **QGEN**. **QGEN** was compared to 60 industry peers in the **Life Sciences Tools & Services** industry. While **QGEN** has a great profitability rating, there are some minor concerns on its financial health. **QGEN** has a correct valuation and a medium growth rate.

In the past year **QGEN** was profitable.

Of the past 5 years **QGEN** 4 years were profitable.

Each year in the past 5 years **QGEN** had a positive operating cash flow.

The **Return On Assets** of **QGEN** (**5.58%**) is better than **80.00%** of its industry peers.

The **Return On Equity** of **QGEN** (**8.96%**) is better than **78.33%** of its industry peers.

With a decent **Return On Invested Capital** value of **7.16%**, **QGEN** is doing good in the industry, outperforming **78.33%** of the companies in the same industry.

Measured over the past 3 years, the **Average Return On Invested Capital** for **QGEN** is in line with the industry average of **9.12%**.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 5.58% | ||

ROE | 8.96% | ||

ROIC | 7.16% |

ROA(3y)6.88%

ROA(5y)5.2%

ROE(3y)12.58%

ROE(5y)9.79%

ROIC(3y)9.15%

ROIC(5y)8.32%

With an excellent **Profit Margin** value of **17.36%**, **QGEN** belongs to the best of the industry, outperforming **88.33%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 22.65% | ||

PM (TTM) | 17.36% | ||

GM | 62.78% |

OM growth 3Y-7.62%

OM growth 5Y2.99%

PM growth 3Y-3.3%

PM growth 5Y6.5%

GM growth 3Y-1.61%

GM growth 5Y-1.22%

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so **QGEN** is still creating some value.

The number of shares outstanding for **QGEN** has been reduced compared to 1 year ago.

The number of shares outstanding for **QGEN** has been reduced compared to 5 years ago.

The debt/assets ratio for **QGEN** has been reduced compared to a year ago.

The **Altman-Z score** of **QGEN** (**3.83**) is better than **65.00%** of its industry peers.

The Debt to FCF ratio of **QGEN** is **5.09**, which is a neutral value as it means it would take **QGEN**, **5.09** years of fcf income to pay off all of its debts.

Looking at the **Debt to FCF ratio**, with a value of **5.09**, **QGEN** is in the better half of the industry, outperforming **80.00%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.24 | ||

Debt/FCF | 5.09 | ||

Altman-Z | 3.83 |

ROIC/WACC0.86

WACC8.37%

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.99 | ||

Quick Ratio | 1.62 |

The earnings per share for **QGEN** have decreased strongly by **-10.68%** in the last year.

The **Revenue** has decreased by **-8.23%** in the past year.

The **Revenue** has been growing slightly by **5.53%** on average over the past years.

EPS 1Y (TTM)-10.68%

EPS 3Y-0.51%

EPS 5Y9.58%

EPS growth Q2Q3.77%

Revenue 1Y (TTM)-8.23%

Revenue growth 3Y1.67%

Revenue growth 5Y5.53%

Revenue growth Q2Q2.24%

Based on estimates for the next years, **QGEN** will show a quite strong growth in **Revenue**. The Revenue will grow by **9.63%** on average per year.

EPS Next Y2.99%

EPS Next 2Y5.8%

EPS Next 3Y8.21%

EPS Next 5Y6.85%

Revenue Next Year5%

Revenue Next 2Y6%

Revenue Next 3Y6.84%

Revenue Next 5Y9.63%

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

The **Price/Earnings** ratio is **20.50**, which indicates a rather expensive current valuation of **QGEN**.

Compared to the rest of the industry, the **Price/Earnings** ratio of **QGEN** indicates a rather cheap valuation: **QGEN** is cheaper than 96.67% of the companies listed in the same industry.

The **Price/Forward Earnings** ratio is **19.93**, which indicates a rather expensive current valuation of **QGEN**.

The average S&P500 **Price/Forward Earnings** ratio is at **21.87**. **QGEN** is around the same levels.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 20.5 | ||

Fwd PE | 19.93 |

95.00% of the companies in the same industry are more expensive than **QGEN**, based on the **Enterprise Value to EBITDA** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 32.42 | ||

EV/EBITDA | 14.88 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates **QGEN** does not grow enough to justify the current Price/Earnings ratio.

The decent profitability rating of **QGEN** may justify a higher PE ratio.

PEG (NY)6.84

PEG (5Y)2.14

EPS Next 2Y5.8%

EPS Next 3Y8.21%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.04% |

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years0

DPN/A

EPS Next 2Y5.8%

EPS Next 3Y8.21%

**QIAGEN N.V.**

NYSE:QGEN (3/1/2024, 7:04:00 PM)

After market: 43.45 0 (0%)**43.45**

**+0.66 (+1.54%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap9.62B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.04% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 20.5 | ||

Fwd PE | 19.93 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)6.84

PEG (5Y)2.14

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 5.58% | ||

ROE | 8.96% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 22.65% | ||

PM (TTM) | 17.36% | ||

GM | 62.78% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.32

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.24 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.99 | ||

Quick Ratio | 1.62 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-10.68%

EPS 3Y-0.51%

EPS 5Y

EPS growth Q2Q

EPS Next Y2.99%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-8.23%

Revenue growth 3Y1.67%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y